Answers are grounded in this paper and cite their sources.
Social media discourse on glucagon-like peptide-1 (GLP-1)-based medicines, including semaglutide and tirzepatide, has expanded rapidly alongside growing public interest in their use for weight management. However, little is known about the accuracy, safety information, and commercial promotion of such online discourse in the Philippines. This study aimed to (1) describe GLP-1-related social media content surfaced in the Philippines from January 2025 to January 2026, (2) evaluate the accuracy of claims relative to current U.S. Food and Drug Administration prescribing information, and (3) determine the extent of safety information presented. Using an exploratory cross-sectional quantitative content analysis, 38 publicly available posts from YouTube, Facebook, and TikTok were identified through purposive keyword searches and analyzed using a structured coding tool covering drug name, creator type, claim accuracy, adverse drug reaction information, contraindications, dosage, commercial intent, and social-media engagement. The sample was dominated by news and media sources (50.0%). Most posts mentioned semaglutide (80.3%) and tirzepatide (42.1%). Fifty percent of posts were coded as fully accurate, 44.7% as partially accurate, and 5.3% as inaccurate. Safety information was inconsistently reported, with the lowest Safety Information Score observed among the sampled TikTok posts. Definite or partial commercial intent was identified in 28.9% of posts. Given the small purposive sample, platform-level differences should be interpreted descriptively. These findings support clearer health-care-professional safety communication, strengthened regulatory surveillance and consumer guidance, and platform-level contextual labeling of GLP-1-related content.
No takes yet. Share an insight, caveat, or question.
Zypher Jude G. Regencia (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: